Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2911-2915

  Maio, M ^a   Danielli, R ^a   Chiarion Sileni, V ^b   Pigozzo, J ^b   Parmiani, G ^c   Ridolfi, R ^d   De Rosa, F ^d   Del Vecchio, M ^e   Di Guardo, L ^e   Queirolo, P ^f   Picasso, V ^f   Marchetti, P ^g,h   De Galitiis, F ^g   Mandala M ⁱ   Guida, M ^j   Simeone, E ^k   Ascierto, P A ^k  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ Bergamo Hospital   (Italy)

^j NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^k NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Efficacy; Expanded access programme; Ipilimumab; Metastatic melanoma; Safety; Uveal melanoma

Indexed keywords

IPILIMUMAB;

ADULT; AGED; ARTICLE; ASTHENIA; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; UVEA MELANOMA;

EFFICACY; EXPANDED ACCESS PROGRAMME; IPILIMUMAB; METASTATIC MELANOMA; SAFETY; UVEAL MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN NEOPLASMS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 84887087345     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt376     Document Type: Article

References (27)

1. Papastefanou VP, Cohen VM. Uveal melanoma. J Skin Cancer 2011; 2011: 573974.
2. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005; 18: 75-84.
3. Diener-West M, Reynolds SM, Agugliaro DJ et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123: 1639-1643.
4. Eskelin S, Pyrhonen S, Summanen P et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107: 1443-1449.
5. Grossniklaus HE. Progression of ocular melanoma metastasis to the liver. JAMA Opthamol 2013; 131: 462-469.
6. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-1693.
7. Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol 1991; 36: 161-195.
8. Kivela T, Suciu S, Hansson J et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39: 1115-1120.
9. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-127.
10. Cohen U, Goldenberg-Cohen N, Parrella P et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 2876-2878.
11. Cruz F, Rubin BP, Wilson D et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63: 5761-5766.
12. Edmunds SC, Cree IA, Di Nicolantonio F et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br J Cancer 2003; 88: 1403-1405.
13. Rimoldi D, Salvi S, Lienard D et al. Lack of BRAF mutations in uveal melanoma. Cancer Res 2003; 63: 5712-5715.
14. Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-2199.
15. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Sem Oncol 2010; 37: 127-138.
16. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
17. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
18. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
19. Khattak MA, Fisher R, Hughes P et al. Ipilimumab activity in advanced uveal melanoma. Melanoma Res 2013; 23: 79-81.
20. Danielli R, Ridolfi R, Chiarion-Sileni V et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother 2012; 61: 41-48.
21. Khan SA, Callahan M, Postow MA et al. Ipilimumab in the treatment of uveal melanoma: the Memorial Sloan-Kettering Cancer Center experience. J Clin Oncol 2012; 30: abstract 8549.
22. Wolchok JD, Weber JS, Maio M et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24: 2174-2180.
23. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-2047.
24. Peters S, Voelter V, Zografos L et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17: 578-583.
25. Queirolo P, Acquati M. Medical treatment of uveal melanoma. Tumori 2007; 93 (Suppl): 27-30.
26. Di Giacomo AM, Danielli R, Guidoboni M et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58: 1297-1306.
27. TM Summary of Product Characteristics. http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/002213/ WC500109299.pdf 2012; (accessed November 2012).